Categories: News

DataPath examines the effects of COVID-19 on COBRA and upcoming ERISA plan deadlines

LITTLE ROCK, Ark., Feb. 16, 2021 /PRNewswire/ — DataPath, Inc., a leading developer of technology solutions for employee benefits administration, has published a whitepaper titled, “COVID-19 and COBRA Continuation Insurance: Where Do We Stand?” The paper takes a deeper look at the effect of the COVID-19 healthcare crisis on the economy – specifically, its impact on the COBRA insurance market – and how an upcoming deadline could wreak havoc for administrators.

In March 2020, the Federal response to the COVID healthcare crisis included a one year “Outbreak Period,” defined by a joint final notice issued by the Internal Revenue Service and Department of Labor as beginning March 1, 2020 and ending February 28, 2021. With the end looming, third party administrators, employers, and insurance carriers could face some serious issues regarding notices to beneficiaries, COBRA elections, and premium payments, all of which were temporarily suspended for the duration of the Outbreak Period. Without additional Federal guidance, administrators and employers could be facing a massive influx of work, deadlines and not the least, confusion.

“COBRA insurance fills a very specific need for people who lose their group healthcare coverage and are in potential crisis situations,” says John Robbins, Jr, President and CEO of DataPath. “The current situation emphasizes the need for a flexible COBRA software solution that allows administrators to address these needs when so many variables are in play, both now and in the future.”

You can download the whitepaper here.

DataPath will be hosting a webinar on Thursday, February 25, at 10:30 AM (CT) to discuss the whitepaper.

About DataPath: DataPath, Inc. was founded in 1984 and is headquartered in Little Rock, Arkansas. DataPath launched its cloud-based Summit platform in 2017, specifically to handle COBRA and  consumer directed healthcare account administration in a single solution. Learn more at dpath.com.

Contact: Erin Carlile, erin@marketingworks360.com, 614-540-5520

 

View original content:http://www.prnewswire.com/news-releases/datapath-examines-the-effects-of-covid-19-on-cobra-and-upcoming-erisa-plan-deadlines-301228341.html

SOURCE DataPath, Inc.

Staff

Recent Posts

AI/ML Innovations Closes Acquisition of Quantum Sciences Ltd.

Strategic Expansion into Cardio AI-Driven Healthcare SolutionsCollaboration to Enhance Patient-Centered Digital Healthcare TechnologiesWelcomes Key Industry…

1 hour ago

cbdMD Announces Company’s CEO Joins the Board of Directors

Charlotte, North Carolina--(Newsfile Corp. - December 23, 2024) - cbdMD, Inc. (NYSE American: YCBD) (NYSE…

15 hours ago

Interactive Strength Inc. (Nasdaq: TRNR) Issues Year-End Update, Looks Ahead to 2025

AUSTIN, TEXAS / ACCESSWIRE / December 23, 2024 / Interactive Strength Inc. (Nasdaq:TRNR) ("TRNR" or…

16 hours ago

Quest Diagnostics Upholds Strong Governance and Ethics With Robust Oversight, ESG Integration, and Comprehensive Risk Management

Originally published in Quest Diagnostics' 2023 Corporate Responsibility ReportNORTHAMPTON, MA / ACCESSWIRE / December 23,…

16 hours ago

Phio Pharmaceuticals Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Marlborough, Massachusetts--(Newsfile Corp. - December 23, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage…

17 hours ago

ILiAD Biotechnologies Announces the Passing of Chief Operating Officer Ken Solovay

WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotech company developing the world’s most…

19 hours ago